Education
About Us
Working with TipRanks
Follow Us
HeraMED Ltd. (DE:1I4)
FRANKFURT:1I4
1I4 Stock Chart & Stats
€0.02
<€0.01(10.00%)
At close: 4:00 PM EST
€0.02
<€0.01(10.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)152.85K
Market Cap
€27.64M
Enterprise Value€21.14M
Total Cash (Recent Filing)€914.65K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,113,653,400
10 Day Avg. Volume114,978
30 Day Avg. Volume152,848
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginSustained gross margins near 60% indicate favorable unit economics for the core device/software mix. That level of gross profitability provides structural capacity to absorb and scale operating expenses, meaning operational improvement could translate into durable operating leverage as revenue stabilizes.
Deleveraged Balance SheetElimination of debt and a return to positive equity materially reduces financial distress risk and interest exposure. This cleaner capital structure improves strategic optionality and reduces near-term cash drain from financing costs, supporting a longer runway for execution against commercial objectives.
Platform-Based Women's Health OfferingA software-plus-connected-device model in women's health targets recurring clinical workflows and care pathways, creating potential recurring revenue and higher customer lifetime value. Structural demand for remote maternal monitoring supports sustained market opportunity and scalable service expansion.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow implies ongoing cash burn and reliance on external financing. Over a 2–6 month horizon this raises liquidity and dilution risk, limits ability to invest in growth initiatives, and forces prioritization of funding needs over organic scaling.
Revenue Volatility And Recent ContractionInconsistent and recently declining revenue undermines visibility and weakens the path to operating leverage. Volatility makes it harder to spread fixed costs, complicates forecasting and commercialization plans, and raises execution risk for converting attractive gross margins into sustainable profits.
Sustained Losses And Negative ReturnsPersistent operating and net losses have eroded the capital cushion and produced negative returns on equity, constraining reinvestment capacity. Continued losses increase the probability of future equity raises and limit long-term capital allocation flexibility, pressuring strategic execution.
HeraMED Ltd. News
1I4 FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is €27.64M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 175 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,113,653,400 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in DE:1I4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-513.22%
Trailing 12-Months
Asset Growth
-54.47%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a digital pregnancy monitor platform for the creation and implementation of digital health solutions for maternity care management. It also develops EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.